TY - JOUR

T1 - Home-based cognitive behavioural therapy for families of young children with cancer (FAMOS)

T2 - A nationwide randomised controlled trial

AU - Salem, Hanin

AU - Kazak, Anne E.

AU - Andersen, Elisabeth Wreford

AU - Belmonte, Federica

AU - Johansen, Christoffer

AU - Schmiegelow, Kjeld

AU - Winther, Jeanette Falck

AU - Wehner, Peder Skov

AU - Hasle, Henrik

AU - Rosthøj, Steen

AU - Bidstrup, Pernille E.

PY - 2021

Y1 - 2021

N2 - Introduction: Evidence-based knowledge is needed to reduce psychological symptoms in families of young children with cancer after treatment ends. Objective: To evaluate the effect of a psychotherapeutic intervention, FAMily-Oriented Support (FAMOS) on parents of young children after cancer treatment. Methods: All families of children aged 0-6 years who had been treated for cancer at one of the four paediatric oncology departments in Denmark were invited to participate after ending intensive medical treatment. The families were randomly assigned 1:1 to up to seven sessions of FAMOS, a cognitive-behavioural manualised home intervention, for 6 months or to usual psychosocial care. The primary outcome was parents’ symptoms of posttraumatic stress disorder (PTSD) at 6 and 12 months after enrolment. The secondary outcomes were parents’ symptoms of depression and anxiety. Results: We enrolled 109 families (204 parents). Parents in the intervention group did not show a statistically significant decrease in symptoms of PTSD as compared with the control group at 6 months (predicted mean difference, −0.10; 95% confidence interval [CI] −0.19, 0.01), but a statistically significant decrease was seen at 12 months (predicted mean difference, −0.15; 95% CI −0.28, −0.02), and they had significantly lower symptoms of depression at both 6 and 12 months. Differences in reductions in symptoms of anxiety were not statistically significant. Conclusions: The FAMOS intervention reduced parents’ symptoms of PTSD and depression. Next step is to also report on psychological effects in the children and siblings (clinicaltrials.gov: NCT02200731).

AB - Introduction: Evidence-based knowledge is needed to reduce psychological symptoms in families of young children with cancer after treatment ends. Objective: To evaluate the effect of a psychotherapeutic intervention, FAMily-Oriented Support (FAMOS) on parents of young children after cancer treatment. Methods: All families of children aged 0-6 years who had been treated for cancer at one of the four paediatric oncology departments in Denmark were invited to participate after ending intensive medical treatment. The families were randomly assigned 1:1 to up to seven sessions of FAMOS, a cognitive-behavioural manualised home intervention, for 6 months or to usual psychosocial care. The primary outcome was parents’ symptoms of posttraumatic stress disorder (PTSD) at 6 and 12 months after enrolment. The secondary outcomes were parents’ symptoms of depression and anxiety. Results: We enrolled 109 families (204 parents). Parents in the intervention group did not show a statistically significant decrease in symptoms of PTSD as compared with the control group at 6 months (predicted mean difference, −0.10; 95% confidence interval [CI] −0.19, 0.01), but a statistically significant decrease was seen at 12 months (predicted mean difference, −0.15; 95% CI −0.28, −0.02), and they had significantly lower symptoms of depression at both 6 and 12 months. Differences in reductions in symptoms of anxiety were not statistically significant. Conclusions: The FAMOS intervention reduced parents’ symptoms of PTSD and depression. Next step is to also report on psychological effects in the children and siblings (clinicaltrials.gov: NCT02200731).

KW - anxiety

KW - cancer

KW - cognitive behavioural psychotherapy

KW - depression

KW - family

KW - posttraumatic stress disorder

KW - randomised controlled trial

U2 - 10.1002/pbc.28853

DO - 10.1002/pbc.28853

M3 - Journal article

C2 - 33369038

AN - SCOPUS:85098163883

VL - 68

JO - Pediatric Blood & Cancer

JF - Pediatric Blood & Cancer

SN - 1545-5009

IS - 3

M1 - e28853

ER -